Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Augstein

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association|July 13, 2025
Residual insulin secretion in long-standing type 1 diabetesPetra Augstein, Natalie Buschmann, Janik Riese, et al.
Biochemical and Biophysical Research Communications|April 25, 2003
Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cellsPetra Augstein, Annemarie Dunger, Peter Heinke, et al.
Journal of Autoimmunity|June 7, 2003
IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destructionGerhild Wachlin, Petra Augstein, Dieter Schröder, et al.
Diabetes & Vascular Disease Research|September 9, 2008
Dominance of cytokine- over FasL-induced impairment of the mitochondrial transmembrane potential (Deltapsim) in the pancreatic beta-cell line NIT-1Petra Augstein, Peter Heinke, Eckhard Salzsieder, et al.
BMC Endocrine Disorders|May 2, 2015
Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapiesPetra Augstein, Peter Heinke, Lutz Vogt, et al.
Journal of Autoimmunity|December 2, 2004
Cytokines activate caspase-3 in insulinoma cells of diabetes-prone NOD mice directly and via upregulation of FasPetra Augstein, Jeanette Bahr, Gerhild Wachlin, et al.
Diabetes Research and Clinical Practice|March 3, 2007
Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetesKlaus-Dieter Kohnert, Petra Augstein, Peter Heinke, et al.
Diabetes Care|February 27, 2009
Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agentsKlaus-Dieter Kohnert, Petra Augstein, Eckhard Zander, et al.
The Journal of Clinical Investigation|May 3, 2003
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptideNathan R Martinez, Petra Augstein, Antonis K Moustakas, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Telemedicine-based KADIS combined with CGMS has high potential for improving outpatient diabetes careEckhard Salzsieder, Petra Augstein, Lutz Vogt, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Diabetic Medicine : a Journal of the British Diabetic Association|July 13, 2025
Residual insulin secretion in long-standing type 1 diabetesPetra Augstein, Natalie Buschmann, Janik Riese, et al.
Biochemical and Biophysical Research Communications|April 25, 2003
Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cellsPetra Augstein, Annemarie Dunger, Peter Heinke, et al.
Journal of Autoimmunity|June 7, 2003
IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destructionGerhild Wachlin, Petra Augstein, Dieter Schröder, et al.
Diabetes & Vascular Disease Research|September 9, 2008
Dominance of cytokine- over FasL-induced impairment of the mitochondrial transmembrane potential (Deltapsim) in the pancreatic beta-cell line NIT-1Petra Augstein, Peter Heinke, Eckhard Salzsieder, et al.
BMC Endocrine Disorders|May 2, 2015
Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapiesPetra Augstein, Peter Heinke, Lutz Vogt, et al.
Journal of Autoimmunity|December 2, 2004
Cytokines activate caspase-3 in insulinoma cells of diabetes-prone NOD mice directly and via upregulation of FasPetra Augstein, Jeanette Bahr, Gerhild Wachlin, et al.
Diabetes Research and Clinical Practice|March 3, 2007
Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetesKlaus-Dieter Kohnert, Petra Augstein, Peter Heinke, et al.
Diabetes Care|February 27, 2009
Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agentsKlaus-Dieter Kohnert, Petra Augstein, Eckhard Zander, et al.
The Journal of Clinical Investigation|May 3, 2003
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptideNathan R Martinez, Petra Augstein, Antonis K Moustakas, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Telemedicine-based KADIS combined with CGMS has high potential for improving outpatient diabetes careEckhard Salzsieder, Petra Augstein, Lutz Vogt, et al.
Pageof 3